Free

E-newsletter

Subscribe to Housecall

Our weekly general interest
e-newsletter keeps you up to date on a wide variety of health topics.

Sign up now

Thalidomide: Research advances in cancer and other conditions

Despite its history, thalidomide has proved effective in treating some diseases. Consider the benefits and risks of thalidomide to help you decide whether this drug may be right for you.

By Mayo Clinic staff

Living With Cancer

Subscribe to our Living With Cancer e-newsletter to stay up to date on cancer topics.

Sign up now

In the 1950s and the early 1960s, thalidomide was used to treat morning sickness during pregnancy. But it was found to cause severe birth defects.

Now, decades later, thalidomide is being used to treat a skin condition and cancer. It's being investigated as a treatment for many other disorders.

Thalidomide proves useful for skin lesions and multiple myeloma

Research into potential uses for thalidomide has determined that thalidomide may be an effective treatment for several conditions. The Food and Drug Administration (FDA) has approved thalidomide (Thalomid) for treating:

  • Skin lesions caused by leprosy (erythema nodosum leprosum)
  • Multiple myeloma

Areas of thalidomide research

Researchers continue to investigate thalidomide for use in treating a variety of diseases and conditions. Though more study is needed, thalidomide has shown promise in treating:

  • Inflammatory diseases that affect the skin, such as cutaneous lupus and Behcet's disease
  • HIV-related mouth and throat ulcers, as well as HIV-related weight loss and body wasting
  • Cancer, including blood and bone marrow cancers, such as leukemia and myelofibrosis, as well as cancers found elsewhere in the body
Next page
(1 of 2)
References
  1. Pan B, et al. The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacology & Therapeutics. 2012;136:56.
  2. Thalomid (prescribing information). Summit, N.J.: Celgene Corp.; 2013. http://www.thalomid.com/thalomid_pi.aspx. Accessed April 22, 2013.
  3. Revlimid (prescribing information). Summit, N.J.: Celgene Corp.; 2013. http://www.revlimid.com. Accessed April 22, 2013.
  4. Pomalyst (prescribing information). Summit, N.J.: Celgene Corp.; 2013. http://www.pomalyst.com. Accessed April 24, 2013.
  5. Goldman L, et al. Cecil Medicine. 24th ed. Philadelphia, Pa.: Saunders Elsevier; 2012. http://www.mdconsult.com/das/book/body/191371208-2/0/1492/0.html#. Accessed April 24, 2013.
  6. Grinspoon SK. Management of tissue wasting in patients with HIV infection. http://www.uptodate.com/home. Accessed April 24, 2013.
HQ01507 June 5, 2013

© 1998-2013 Mayo Foundation for Medical Education and Research (MFMER). All rights reserved. A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.com," "EmbodyHealth," "Enhance your life," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.

  • Reprints
  • Print
  • Share on:

  • Email

Advertisement


Text Size: smaller largerlarger